Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Moderate to Severe

Pediatric Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

Woman in a blue dress smiles

1 injection, 4 times a year

after week 0 and 4 injections1

SKYRIZI® Pen

Reliable 3-MONTH DOSING1

ADMINISTERED BY A SINGLE 150 mg/mL SUBCUTANEOUS INJECTION AT:

Initiation

SKYRIZI® Pen

WEEK 0

SKYRIZI® Pen

WEEK 4

Month 3

SKYRIZI® Pen

WEEK 16

Month 6

SKYRIZI® Pen

WEEK 28

Month 9

SKYRIZI® Pen

WEEK 40

Month 12

SKYRIZI® Pen

WEEK 52

FLEXIBILITY to choose between the 150 mg/mL single-dose pen or 150 mg/mL single-dose prefilled syringe

3-MONTH DOSING

after 2 initiation doses
(150 mg dose) at Weeks 0 and 4

2 administration options

for in-office or at-home administration after proper training

1 DOSAGE
FOR ALL PATIENTS

regardless of baseline weight,
disease severity, or prior treatment


Dosing Considerations

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1

SKYRIZI® dosing card

Download OR EMAIL
DOSING CARD

Download or Email

Dosing Considerations

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.1

SKYRIZI® dosing card

Download OR EMAIL
DOSING CARD

Download or Email

INJECTION SUPPORT VIDEOS

150 mg/mL
SKYRIZI PEN

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support.

150 mg/mL
PREFILLED SYRINGE

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support.

Download
Dosing card


Download or Email

SKYRIZI® dosing card

Dosing Schedules

Dosing schedules FOR IL-17 and IL-23 INHIBITORS1-6

TREATMENT INITIATION

SKYRIZI® (risankizumab-rzaa)

Dosing: 150 mg (two 75 mg subcutaneous injections); every 12 weeks after initiation

 

ILUMYA™ (tildrakizumab-asmn)

Dosing: 100 mg subcutaneous injection; every 12 weeks after initiation

 

TREMFYA® (guselkumab)

Dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

 

Taltz (ixekizumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

 

COSENTYX® (secukinumab)

Dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

 

SILIQ® (brodalumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

 

.

.

Initiation doses at Weeks 0 and 4

 

 

.

.

Initiation doses at Weeks 0 and 4

 

 

.

.

.

.

.

.

.

160 mg (two 80 mg injections) at Week 0 following by 80 mg every 2 weeks through Week 12

 

 

.

.

.

.

.

Once-weekly dosing for the first 5 doses

 

 

.

.

.

Initiation doses at Weeks 0, 1, and 2

YEARLY DOSING* (AFTER INITIATION)

Every 12 Weeks

Total of 4 doses a year

 

Every 12 Weeks

Total of 4 doses a year

 

Every 8 Weeks

Total of 6 doses a year

 

Every 4 Weeks

Total of 12 doses a year

 

Every 4 Weeks

Total of 12 doses a year

 

Every 2 Weeks

Total of 24 doses a year

.

.

.

.

 

 

 

.

.

.

.

 

 

 

.

.

.

.

.

.

 

 

 

.

.

.

.

.

.

.

.

.

.

.

.

 

 

 

.

.

.

.

.

.

.

.

.

.

.

.

 

 

 

.

.

.

.

.

.

.

.

.

.

.

.


.

.

.

.

.

.

.

.

.

.

.

.

TREATMENT INITIATION

SKYRIZI® (risankizumab-rzaa)

Dosing: 150 mg (two 75 mg subcutaneous injections); every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

ILUMYA™ (tildrakizumab-asmn)

Dosing: 100 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

TREMFYA® (guselkumab)

Dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

Taltz (ixekizumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

.

.

.

.

.

.

.

160 mg (two 80 mg injections) at Week 0 following by 80 mg every 2 weeks through Week 12

 

COSENTYX® (secukinumab)

Dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

.

.

.

.

.

Once-weekly dosing for the first 5 doses

 

SILIQ® (brodalumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

.

.

.

Initiation doses at Weeks 0, 1, and 2

YEARLY DOSING* (AFTER INITIATION)

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

Every 8 Weeks

Total of 6 doses a year

.

.

.

.

.

.

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

 

Every 2 Weeks

Total of 24 doses a year

.

.

.

.

.

.

.

.

.

.

.

.


.

.

.

.

.

.

.

.

.

.

.

.

TREATMENT INITIATION

SKYRIZI® (risankizumab-rzaa)

Dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

ILUMYA® (tildrakizumab-asmn)

Dosing: 100 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

TREMFYA® (guselkumab)

Dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

Taltz® (ixekizumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

.

.

.

.

.

.

.

160 mg (two 80 mg injections) at Week 0 followed by 80 mg every 2 weeks through Week 12

COSENTYX® (secukinumab)

Dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

.

.

.

.

.

Once-weekly dosing for the first 5 doses

SILIQ® (brodalumab)

Dosing: 210 mg subcutaneous injection; every 2 weeks after initiation

.

.

.

Initiation doses at Weeks 0, 1, and 2

YEARLY DOSING* (AFTER INITIATION)

SKYRIZI® (risankizumab-rzaa)

Dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

ILUMYA® (tildrakizumab-asmn)

Dosing: 100 mg subcutaneous injection; every 12 weeks after initiation

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

TREMFYA® (guselkumab)

Dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

Every 8 Weeks

Total of 6 doses a year

.

.

.

.

.

.

Taltz® (ixekizumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

COSENTYX® (secukinumab)

Dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

 

SILIQ® (brodalumab)

Dosing: 210 mg subcutaneous injection; every 2 weeks after initiation

Every 2 Weeks

Total of 24 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

.


.

.

.

.

.

.

.

.

.

.

.

TREATMENT INITIATION

SKYRIZI® (risankizumab-rzaa)

Dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

ILUMYA® (tildrakizumab-asmn)

Dosing: 100 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

TREMFYA® (guselkumab)

Dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

Taltz® (ixekizumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

.

.

.

.

.

.

.

160 mg (two 80 mg injections) at Week 0 followed by 80 mg every 2 weeks through Week 12

COSENTYX® (secukinumab)

Dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

.

.

.

.

.

Once-weekly dosing for the first 5 doses

SILIQ® (brodalumab)

Dosing: 210 mg subcutaneous injection; every 2 weeks after initiation

.

.

.

Initiation doses at Weeks 0, 1, and 2

YEARLY DOSING* (AFTER INITIATION)

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

Every 8 Weeks

Total of 6 doses a year

.

.

.

.

.

.

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

 

Every 2 Weeks

Total of 24 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

.


.

.

.

.

.

.

.

.

.

.

.

Dosing Schedules For IL-17 And IL-23 Inhibitors Dosing Schedules For IL-17 And IL-23 Inhibitors Dosing Schedules For IL-17 And IL-23 Inhibitors

This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.

*Based on doses required in each 48-week maintenance treatment period.

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to read the Instructions for Use before administration.1

TREATMENT INITIATION

YEARLY DOSING* (AFTER INITIATION)

SKYRIZI® (risankizumab-rzaa)

Dosing: 150 mg (two 75 mg subcutaneous injections); every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

ILUMYA™ (tildrakizumab-asmn)

Dosing: 100 mg subcutaneous injection; every 12 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

Every 12 Weeks

Total of 4 doses a year

.

.

.

.

TREMFYA® (guselkumab)

Dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

.

.

Initiation doses at Weeks 0 and 4

Every 8 Weeks

Total of 6 doses a year

.

.

.

.

.

.

Taltz (ixekizumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

.

.

.

.

.

.

.

160 mg (two 80 mg injections) at Week 0 following by 80 mg every 2 weeks through Week 12

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

COSENTYX® (secukinumab)

Dosing: 300 mg (two 150 mg injections); every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

.

.

.

.

.

Once-weekly dosing for the first 5 doses

Every 4 Weeks

Total of 12 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

 

SILIQ® (brodalumab)

Dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

.

.

.

Initiation doses at Weeks 0, 1, and 2

Every 2 Weeks

Total of 24 doses a year

.

.

.

.

.

.

.

.

.

.

.

.

.


.

.

.

.

.

.

.

.

.

.

.

SKYRIZI® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ILUMYA® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Taltz® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

COSENTYX®is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

SILIQ® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.


See SkyriziResults

after 1 dose7

Patient Icon

Enroll patients in SKYRIZI complete

Resources for your patients

Checkmark Icon
ISI and Indication
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210127

REFERENCES

  1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
  2. ILUMYA [package insert]. Princeton, NJ; Sun Pharmaceuticals, Inc.
  3. TREMFYA [package insert]. Horsham, PA; Janssen Biotech, Inc.
  4. Taltz [package insert]. Indianapolis, IN; Eli Lilly and Company.
  5. COSENTYX [prescribing information]. East Hanover, NJ; Novartis Pharmaceuticals Corporation.
  6. SILIQ [package insert]. Bridgewater, NJ; Valeant Pharmaceuticals North America LLC.
  7. Lebwohl M, Bachelez H, Valdecantos WC, Wu T, Gordon K. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis: an integrated analysis of UltIMMa-1 and UltIMMa-2. Poster presented at: American Academy of Dermatology Annual Meeting; March 1-5, 2019; Washington, DC.

Dosing schedules FOR IL-17 and IL-23 INHIBITORS1-6

asfaf

asfaf

asfaf

asfaf

asfaf

asfaf

Dosing Schedules For IL-17 And IL-23 Inhibitors Dosing Schedules For IL-17 And IL-23 Inhibitors Dosing Schedules For IL-17 And IL-23 Inhibitors

This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.

*Based on doses required in each 48-week maintenance treatment period.

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to inject 2 prefilled 75 mg syringes for the full 150 mg dose and to read the Instructions for Use before administration.

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210127